Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2012

View Archived Issues

New Pfizer product shows promising anticancer actvity

Genentech presents PK/PD model for IBD therapy

Companies seek approval in Japan for biosimilar of filgrastim

New promising results disclosed on brodalumab in plaque psoriasis

New technology launched by arGEN-X

Xention discloses encouraging phase I data on candidate AF drug

Shire exercises option to license candidate agent for CNS disorders

Scientists identify new potential biomarker of myxoid/round cell liposarcoma

Halo Therapeutics reports on independent review of lead product

PROLOR Biotech launches pediatric trial of long-acting human growth hormone

Proteonomix announces completion of private placement

Patrys reports on phase I PAT-SM6 trial

Taisho reports novel sodium/glucose cotransporter 1 inhibitors

New candidate pain therapies designed at Gruenenthal

Novel inhibitors of MPGES-1 developed

Cedars-Sinai Medical Center presents new potential atherosclerosis therapies

Karo Bio scientists discover new ER-beta ligands

Aerpio discloses phase I data on agent for diabetic macular edema

EMA accepts lomitapide MAA for review

First patient enrolled in phase I/II study of PET imaging agent for brain cancer

Milestone reached in OncoTherapy Science/Shionogi collaboration

Taiho and Nordic Group launch Teysuno

Telotristat etiprate receives FDA orphan drug status

FDA's ODAC votes regarding approval of ridaforolimus

GSK gives update on FDA's ODAC review of Votrient

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...